Loading...
Please wait, while we are loading the content...
Similar Documents
Promises and challenges in the engineering of nanosized active pharmaceutical ingredients
| Content Provider | Semantic Scholar |
|---|---|
| Copyright Year | 2016 |
| Abstract | The advances in the field of nanotechnology have revolutionized the field of delivery of poorly soluble active pharmaceutical ingredients (APIs). Nanoparticles refer to solid colloidal threedimensional particles in the size range from (1 to 1000) nm. Therapeutically, nanoparticles could be used as API carriers (vehicles) through dissolving, entrapping or adsorbing the API. Historically, nanoparticles have been developed for API delivery since the 1960s. Commercially, the first approved product employing nanoparticle formulation was ABI-007 (Abraxane®; American BioScience Inc., Santa Monica, CA). Nanotechnologies have been used for the treatment of several diseases such as cancer, tuberculosis, etc. Nanosized formulations have been extensively investigated to achieve a rapid dissolution and therefore pharmacokinetic properties similar to those observed in solutions. The present review outlines the recent advances, promises and challenges of the engineering nanosized APIs. The principles, merits, demerits and applications of the current 'bottom-up' and 'top-down' technologies by which the state of the art nanosized APIs can be produced were described. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://atlasofscience.org/wp-content/uploads/wp-post-to-pdf-enhanced-cache/1/promises-and-challenges-in-the-engineering-of-nanosized-active-pharmaceutical-ingredients.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
